<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Patterns of long-term use of non-vitamin K antagonist oral anticoagulants for non-valvular atrial fibrillation: Quebec observational study</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">Antonios</forename><surname>Douros</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Centre for Clinical Epidemiology</orgName>
								<orgName type="institution">Lady Davis Institute -Jewish General Hospital</orgName>
								<address>
									<settlement>Montreal</settlement>
									<region>Quebec</region>
									<country key="CA">Canada</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department">Department of Epidemiology and Biostatistics</orgName>
								<orgName type="institution">McGill University</orgName>
								<address>
									<settlement>Montreal</settlement>
									<region>Quebec</region>
									<country key="CA">Canada</country>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="institution" key="instit1">Charité -Universitätsmedizin Berlin</orgName>
								<orgName type="institution" key="instit2">Freie Universität Berlin</orgName>
							</affiliation>
							<affiliation key="aff3">
								<orgName type="department">Institute of Clinical Pharmacology and Toxicology</orgName>
								<orgName type="institution" key="instit1">Humboldt-Universität zu Berlin</orgName>
								<orgName type="institution" key="instit2">Berlin Institute of Health</orgName>
								<address>
									<postCode>10117</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Christel</forename><surname>Renoux</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Centre for Clinical Epidemiology</orgName>
								<orgName type="institution">Lady Davis Institute -Jewish General Hospital</orgName>
								<address>
									<settlement>Montreal</settlement>
									<region>Quebec</region>
									<country key="CA">Canada</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department">Department of Epidemiology and Biostatistics</orgName>
								<orgName type="institution">McGill University</orgName>
								<address>
									<settlement>Montreal</settlement>
									<region>Quebec</region>
									<country key="CA">Canada</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Janie</forename><surname>Coulombe</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Centre for Clinical Epidemiology</orgName>
								<orgName type="institution">Lady Davis Institute -Jewish General Hospital</orgName>
								<address>
									<settlement>Montreal</settlement>
									<region>Quebec</region>
									<country key="CA">Canada</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department">Department of Epidemiology and Biostatistics</orgName>
								<orgName type="institution">McGill University</orgName>
								<address>
									<settlement>Montreal</settlement>
									<region>Quebec</region>
									<country key="CA">Canada</country>
								</address>
							</affiliation>
						</author>
						<author role="corresp">
							<persName><roleName>Dr</roleName><forename type="first">Samy</forename><surname>Suissa</surname></persName>
							<email>samy.suissa@mcgill.ca</email>
							<affiliation key="aff0">
								<orgName type="department">Centre for Clinical Epidemiology</orgName>
								<orgName type="institution">Lady Davis Institute -Jewish General Hospital</orgName>
								<address>
									<settlement>Montreal</settlement>
									<region>Quebec</region>
									<country key="CA">Canada</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department">Department of Epidemiology and Biostatistics</orgName>
								<orgName type="institution">McGill University</orgName>
								<address>
									<settlement>Montreal</settlement>
									<region>Quebec</region>
									<country key="CA">Canada</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff4">
								<orgName type="department">Centre for Clinical Epidemiology</orgName>
								<orgName type="institution">Jewish General Hospital</orgName>
								<address>
									<addrLine>3755 Cote Ste-Catherine</addrLine>
									<postCode>H-461, H3T 1E2</postCode>
									<settlement>Montreal</settlement>
									<region>Québec</region>
									<country key="CA">Canada</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff5">
								<orgName type="department">Department of Medicine Research Symposium</orgName>
								<orgName type="institution">McGill University</orgName>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff6">
								<orgName type="department">Canadian Foundation for Innovation, and Bayer</orgName>
								<orgName type="institution">Canadian Institutes of Health Research</orgName>
							</affiliation>
						</author>
						<title level="a" type="main">Patterns of long-term use of non-vitamin K antagonist oral anticoagulants for non-valvular atrial fibrillation: Quebec observational study</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="MD5">375641BA8CD6916A3DEC3077A14506AF</idno>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:40+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>treatment persistence</term>
					<term>drug utilization</term>
					<term>pharmacoepidemiology</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Real-life data on long-term drug utilization of NOACs in non-valvular atrial fibrillation are still scarce.</s><s> Our population-based cohort study showed that patients of advanced age with high thromboembolic risk were less likely to initiate treatment with NOACs than with VKAs.</s><s> One out of four patients initiating VKAs switched from VKAs to NOACs during the study period.</s></p><p><s> NOAC users showed a higher treatment persistence than VKA users in the first 3 years.</s></p><p><s> Patients of advanced age with high thromboembolic risk were less likely to discontinue treatment with oral anticoagulants.</s></p><p><s>Manuscript word count (excl.</s><s>references, tables and figure legends; limit 3000</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>CHA2DS2-VASc ≥ 2 (HR 0.64, 95% CI 0.57-0.70).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conclusions</head><p><s>Older, high-risk patients are less likely to initiate NOACs than VKAs.</s><s>NOAC users show a higher long-term persistence than VKA users, and older, high-risk patients are less likely to discontinue anticoagulation treatment.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>INTRODUCTION</head><p><s>Atrial fibrillation (AF) is a common cardiac arrhythmia currently affecting about 2.3 million people in the United States. <ref type="bibr" target="#b0">1</ref> It increases 5-fold the risk of stroke and 2-fold the risk of mortality, <ref type="bibr" target="#b1">2</ref> and the 30-day case-fatality in patients with AF is approximately 10%. <ref type="bibr" target="#b3">3</ref> In preventing stroke and stroke associated mortality in AF, vitamin K antagonists (VKAs) have long been the gold standard.</s></p><p><s>However, VKAs are prone to drug-drug interactions and depict a narrow therapeutic window, which necessitates monitoring to keep patients within a specific range of International Normalized Ratio (INR). <ref type="bibr" target="#b4">4</ref></s><s>Moreover, the observed treatment persistence, i.e., the duration of time between drug initiation and drug discontinuation, is low, since up to 40% of VKA patients discontinue their therapy during the first 12 months. <ref type="bibr" target="#b5">5</ref></s><s>e non-vitamin antagonist oral anticoagulants (NOACs) showed similar or improved efficacy and safety compared to VKAs in randomized controlled trials in patients with nonvalvular atrial fibrillation (NVAF), <ref type="bibr" target="#b6">6</ref> and are simpler to use since they do not require INR monitoring.</s><s>However, more data on real-life utilization of NOACs are needed.</s><s>]<ref type="bibr" target="#b9">[9]</ref><ref type="bibr" target="#b10">[10]</ref><ref type="bibr" target="#b11">[11]</ref> Moreover, reasons for switching from VKAs to NOACs remain largely elusive. <ref type="bibr" target="#b12">12,</ref><ref type="bibr" target="#b13">13</ref></s><s>In addition, although several studies comparing treatment persistence among NOAC and VKA users have detected higher rates in the former group, the majority of them had a limited follow-up. <ref type="bibr" target="#b5">5,</ref><ref type="bibr" target="#b14">14</ref></s><s>.</s></p><p><s>Thus, the objective of this study was to evaluate treatment initiation, switching, and persistence in patients with NVAF under oral anticoagulation based on a population-based cohort with long-term follow-up.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>METHODS</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Data source</head><p><s>This study used the computerized databases of the Canadian Province of Quebec's health insurance (RAMQ), which is responsible for administering universal healthcare services for the province of Québec, Canada.</s><s>The RAMQ contains information on demographics, medical services, hospital discharges, and filled outpatient drug prescriptions.</s><s>It has been extensively used for research purposes in the past, <ref type="bibr" target="#b15">[15]</ref><ref type="bibr" target="#b16">[16]</ref><ref type="bibr" target="#b17">[17]</ref><ref type="bibr" target="#b18">[18]</ref><ref type="bibr" target="#b19">[19]</ref><ref type="bibr" target="#b20">[20]</ref><ref type="bibr" target="#b21">[21]</ref> including studies on oral anticoagulation in patients with NVAF. <ref type="bibr" target="#b22">22</ref></s><s>The accuracy of linkage between the single RAMQ databases has been shown to be high. <ref type="bibr" target="#b15">15,</ref><ref type="bibr" target="#b23">23</ref></s><s>A detailed description of their structure can be found elsewhere. <ref type="bibr" target="#b22">22</ref></s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Study population</head><p><s>From the source population of all individuals in the RAMQ, we identified all patients ≥ 40 years of age, with a first inpatient or outpatient diagnosis of AF between January 1, 2006 and   December 31, 2014.</s><s>This time period spanned both the periods before and after the introduction of dabigatran as the first NOAC for the treatment of NVAF in Quebec, i.e., January 2011.</s><s>Cohort entry was defined as the date of the first inpatient or outpatient AF diagnosis.</s><s>If the diagnosis occurred during hospitalization, cohort entry was defined as the date of hospital discharge.</s><s>All cohort members were required to have RAMQ medication coverage for at least 1 year prior to cohort entry to provide sufficient baseline information on comorbidities and prior medication use.</s></p><p><s>To confirm the incident nature of the NVAF diagnosis, we excluded all patients with any mention of AF prior to cohort entry or with a history of mitral stenosis, valvular repair, prosthetic heart valve, or hyperthyroidism.</s><s>Moreover, in order to consider only incident users of oral anticoagulants, we further excluded patients with a prescription of any oral anticoagulant in the last year before cohort entry.</s><s>All cohort members were followed until the patient's date of emigration, leaving the prescription drug program, death or end of study period, i.e.</s><s>December 31, 2014.</s><s>All outpatient prescriptions for NOACs approved for NVAF in Quebec during the study period (i.e., dabigatran, rivaroxaban, apixaban) and for VKAs, which were dispensed during follow-up were identified.</s><s>For each prescription, the dispensing date along with product name, drug formulation, dose and duration were obtained.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Study outcomes</head><p><s>The study outcomes were the following: (i) initiation of anticoagulant treatment with NOACs relative to VKAs, (ii) treatment switch from VKAs to NOACs, and (iii) treatment persistence.</s><s>Persistence of use for NOACs or VKAs was quantified for each patient as the time to treatment discontinuation.</s><s>Thus, the first treatment received after cohort entry was identified and every subsequent prescription of this treatment with its duration was applied to calculate the continuous use of the initiating treatment.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Exposure definition</head><p><s>Patients were considered continuously exposed (persistent) to VKAs or NOACs if the duration of 1 prescription overlapped with the date of the subsequent prescription.</s><s>In the event of non-overlap, we allowed for a 30-day grace period between 2 successive prescriptions to account for delays in refilling and variations in patient drug adherence.</s><s>Overlaps in prescription times were not cumulated.</s><s>Treatment switches were considered as treatment discontinuation except for switches within the same group of oral anticoagulants (e.g., from 1 NOAC to another NOAC).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Covariates</head><p><s>Covariates measured at cohort entry included age, sex, calendar year of NVAF diagnosis, time from NVAF diagnosis to anticoagulant treatment initiation, and in-hospital NVAF diagnosis.</s></p><p><s>Baseline comorbidities were measured in the year prior to cohort entry and included cardiovascular comorbidities (arterial hypertension, myocardial infarction, diabetes mellitus, venous thromboembolism, congestive heart failure, ischemic stroke, vascular disease), prior bleeding events (intracranial hemorrhage, gastrointestinal bleeding, other bleedings), blood dyscrasias, predisposition to falls, dementia or schizophrenia, liver disease, chronic kidney disease, and cancer.</s><s>The CHA2DS2-VASc score (congestive heart failure, arterial hypertension, age ≥ 75</s></p><p><s>[doubled], diabetes mellitus, stroke [doubled], vascular disease, age 65-74, sex category: female sex) was computed for the year period prior to cohort entry to assess thromboembolic risk. <ref type="bibr" target="#b24">24</ref></s><s>reover, the use of antiplatelet agents between cohort entry and anticoagulant treatment initiation was assessed.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Data analysis</head><p><s>To identify predictors of treatment initiation with NOACs relative to VKAs after NVAF diagnosis, a logistic regression model was used.</s><s>For each predictor crude and adjusted odds ratios (ORs) of NOAC treatment initiation were estimated along with their 95% confidence intervals (CIs).</s><s>This analysis was restricted to the cohort of patients diagnosed after January 2011 who had the possibility to initiate either drug.</s><s>The cohort of patients diagnosed with NVAF prior to January 2011 was used to provide a baseline measure of VKA initiators in the absence of NOACs.</s></p><p><s>To identify predictors of switching to NOACs relative to remaining on VKAs, a Cox proportional hazards model was used.</s><s>For each predictor crude and adjusted hazard ratios (HRs) of switching from initial VKA treatment to a NOAC were estimated along with their 95% CIs.</s></p><p><s>The analysis was conducted in the cohort initiating VKAs in or after January 2011, from the first VKA prescription to the minimum date among switch to NOACs, end of study, end of insurance, or death.</s></p><p><s>To identify predictors of treatment discontinuation (end or persistence) in users of oral anticoagulants, a Cox proportional hazards model was used.</s><s>For each predictor crude and adjusted HRs of anticoagulant treatment discontinuation were estimated along with the corresponding 95% CIs.</s><s>Moreover, Kaplan-Meier curves were used to plot the probability of persistence with NOACs or VKAs for the first 3 years of treatment.</s><s>The analysis of treatment persistence was based on the cohort of patients diagnosed with NVAF in or after January 2011 who had initiated VKAs or NOACs.</s><s>The cohort of patients diagnosed with NVAF prior to January 2011 was used to provide a baseline measure of VKA persistence in the absence of NOACs.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Sensitivity analyses</head><p><s>We conducted 2 sensitivity analyses to test the robustness of our results on treatment persistence.</s><s>First, we used difference grace periods (60 days or 50% of the duration of the last prescription) to define continuous drug exposure (persistence) in case of non-overlapping prescriptions. <ref type="bibr" target="#b22">22</ref></s><s>Second, the probability of treatment persistence for the first 3 years of treatment was replotted using Kaplan-Meier curves after defining switchers from VKAs to NOACs and vice versa as continuous users of the initial treatment, in order to assess persistence of overall oral anticoagulation.</s><s>All statistical procedures were performed with SAS version 9.4 (SAS Institute Inc., Cary, NC).</s><s>Database access was approved by the Commission d'accès à l'information and the study protocol by the Ethics Committee of the Jewish General Hospital, Montreal, QC, Canada.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>RESULTS</head><p><s>The source population included 323,289 subjects with at least 1 diagnosis code of AF during the period 2006-2014, with a total of 138,616 patients satisfying study cohort criteria (Figure <ref type="figure">1</ref>).</s></p><p><s>Of those, 62,867 were diagnosed with NVAF in or after January 2011, when NOACs became available, with 32,431 (52%) initiating oral anticoagulant treatment between 2011 and 2014.</s><s><ref type="table" target="#tab_1">2</ref>).</s><s>The treatment switch analysis showed that prior myocardial infarction, prior venous thromboembolism, and chronic kidney disease were associated with the lowest probability of switching from VKAs to NOACs as compared to remain on VKAs.</s><s>In contrast, age 50-69 years, NVAF diagnosis after 2011, and liver disease were associated with the highest probability of switching from VKAs to NOACs as compared to remain on VKAs.</s><s>Among the 14,746 patients diagnosed with NVAF in or after January 2011 initiating NOACs, 789 (5%) switched to VKAs during follow-up.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Table 1 displays the baseline characteristics of patients diagnosed with NVAF in or after</head><p><s>The treatment discontinuation analysis showed that initiation of NOACs, age ≥ 50 years, and a CHA2DS2-VASc score ≥ 2 were associated with the lowest risk of discontinuation of oral anticoagulation (Table <ref type="table" target="#tab_2">3</ref>).</s><s>In contrast, delayed treatment initiation following NVAF diagnosis (&gt;180 days), prior myocardial infarction, prior venous thromboembolism, and non-intracranial, non-gastrointestinal bleedings were associated with the highest risk of discontinuation of oral anticoagulation (Table <ref type="table" target="#tab_2">3</ref>).</s><s>Table <ref type="table" target="#tab_3">4</ref> presents the adjusted HRs and corresponding 95% CIs of treatment discontinuation of NOACs relative to VKAs.</s><s>NOAC users were 55% less likely to discontinue their treatment than VKA users, which corresponds to more than a doubling of the probability of treatment persistence in NOAC users (HR 2.22, 95% CI 2.13-2.27).</s><s>The median treatment persistence among those diagnosed in or after January 2011 was 12 months for VKA initiators and 43 months for NOAC initiators.</s><s>Figure <ref type="figure">2</ref> shows that 3 years after treatment initiation, 54% of patients receiving NOACs were persistent compared to 25% of patients receiving VKAs.</s><s>In patients initiating VKAs before 2011, the probability of treatment persistence after 3 years was 29%, while the median treatment persistence was 14 months.</s></p><p><s>The results remained consistent in our sensitivity analyses.</s><s>After applying different grace periods, the rates of treatment persistence after 3 years were higher with NOACs as compared with VKAs (grace period 60 days: 65% for NOACs versus 39% for VKAs; grace period 50% of the duration of the last prescription: 30% for NOACs versus 7% for VKAs).</s><s>Moreover, after defining switchers from VKAs to NOACs and vice versa as continuous users of the initial treatment, treatment persistence after 3 years remained the same for both initial NOAC (54%) and VKA (25%) users as compared to the main analysis.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>DISCUSSION</head><p><s>This observational population-based cohort study of NVAF patients identified factors associated with treatment initiation with NOACs, and with treatment switching from VKAs to NOACs.</s><s>Moreover, it provided an in-depth analysis of long-term treatment persistence among oral anticoagulant users.</s></p><p><s>In line with previous studies, we observed an underuse of oral anticoagulants in our cohort, since every second NVAF patient did not initiate NOACs or VKAs during the study period. <ref type="bibr" target="#b7">7,</ref><ref type="bibr" target="#b25">25</ref></s><s>Of note, among initiators of oral anticoagulants previously receiving antiplatelet drugs, 14% of NOAC users and 27% of VKA users continued their antiplatelet treatment after initiating oral anticoagulation (defined as 2 or more antiplatelet prescriptions in the 3 months following initiation of anticoagulant).</s><s>Although VKA initiators slightly outnumbered NOAC initiators overall, there was an increasing tendency towards NOAC initiation after 2011, which agrees with recent studies from other countries. <ref type="bibr" target="#b11">11,</ref><ref type="bibr" target="#b26">26,</ref><ref type="bibr" target="#b27">27</ref></s><s>Moreover, our data showed that patients of advanced age with a CHA2DS2-VASc score ≥ 2 were less likely to initiate NOACs.</s><s>Given the underrepresentation of very old, high-risk patients in clinical trials, <ref type="bibr" target="#b28">[28]</ref><ref type="bibr" target="#b29">[29]</ref><ref type="bibr" target="#b30">[30]</ref> these findings could reflect the reluctance of physicians to prescribe NOACs in this population.</s><s>Patients with chronic kidney disease were also less likely to initiate NOACs, indicating that the primarily renal clearance of NOACs leads physicians to prefer VKAs in case of impaired kidney function to avoid drug accumulation and increased toxicity risks. <ref type="bibr" target="#b11">11,</ref><ref type="bibr" target="#b31">31</ref></s><s> observed that 27% of the VKA initiators in our cohort switched from VKAs to NOACs during follow-up, with the percentage for NOAC-to-VKA switchers being 5%.</s><s>To date, reported rates of switching among groups of oral anticoagulants vary considerably. <ref type="bibr" target="#b11">11,</ref><ref type="bibr" target="#b32">32</ref></s><s>To our knowledge, our study is the first to systematically assess predictors of switching from initial VKA treatment to NOACs.</s><s>Its findings highlight the influence of pharmacokinetics in this regard, since patients with chronic kidney disease were less likely to switch from VKAs to the predominantly renally excreted NOACs, and patients with liver disease were more likely to switch from the biliary excreted VKAs to NOACs. <ref type="bibr" target="#b4">4</ref> We also observed that advanced age and high thromboembolic risk were associated with a decreased risk of anticoagulant treatment discontinuation, i.e., a higher probability of treatment persistence, corroborating thus previous studies. <ref type="bibr" target="#b10">10,</ref><ref type="bibr" target="#b22">22</ref></s><s>NOAC users had a 55% reduced risk of treatment discontinuation as compared to VKA users, and treatment persistence with NOACs was considerably higher than with VKAs after the first 3 years (54% versus 25%), which is congruent with published data <ref type="bibr" target="#b5">5,</ref><ref type="bibr" target="#b11">11</ref> and compatible with the simpler use of NOACs as compared to VKAs.</s></p><p><s>Importantly, most of the previous studies on anticoagulant treatment persistence had a maximum follow-up of up to 2 years. <ref type="bibr" target="#b5">5</ref></s><s>As patterns of persistence can change over time, <ref type="bibr" target="#b33">33</ref> our findings corroborate recently published data <ref type="bibr" target="#b11">11</ref> showing a higher persistence with NOACs as compared to VKAs also in the long term.</s><s>Finally, since persistence with VKAs in pre-2011 initiators of the 'VKA only' era was similar to that in post-2011 initiators, introducing NOACs seems to have doubled treatment persistence with oral anticoagulants among NVAF patients in Quebec.</s></p><p><s>Our study has several strengths.</s><s>First, it is based on one of the largest and most recent population-based cohorts of NVAF patients, which enables the generalization of its results to NVAF patients from similar health care systems, and the calculation of precise and contemporary estimates for different aspects of utilization of oral anticoagulants in a real-world setting.</s><s>Second, it is the first to concomitantly assess predictors of anticoagulant treatment initiation, treatment switch and treatment discontinuation, while having one of the longest follow-up periods.</s><s>Finally, by considering also the pre-2011 period, we were able to compare anticoagulant treatment persistence in NVAF in Quebec before and after the introduction of NOACs.</s></p><p><s>Our study also has some limitations.</s><s>First, it is likely that the initiation of oral anticoagulation could have occurred in hospital prior to discharge, but the RAMQ does not contain data on inpatient prescriptions.</s><s>However, it is expected that patients initiating anticoagulation therapy would be closely followed in the outpatient setting after hospital discharge, minimizing this potential exposure misclassification.</s><s>Second, data on lifestyle risk factors including smoking or obesity are not available in the RAMQ.</s><s>Thus, their impact on oral anticoagulant treatment could not be evaluated.</s><s>Finally, the study was underpowered to assess predictors of switching from NOACs to VKAs.</s></p><p><s>In summary, an increasing number of newly diagnosed NVAF patients in Quebec receive NOACs as the initial oral anticoagulation, but advanced age and high thromboembolic risk are associated with a lower probability of initiating NOACs compared to VKAs.</s><s>Pharmacokinetics influence both treatment initiation and switching in oral anticoagulation.</s><s>Finally, NVAF patients on NOACs show a higher long-term treatment persistence than patients on VKAs, and the introduction of NOACs has doubled treatment persistence.</s><s>Drug utilization studies with even longer follow-up could help further corroborate these findings.</s><s>NOACs = non-vitamin K antagonist oral anticoagulants; VKAs = vitamin K antagonists; NVAF = non-valvular atrial fibrillation; HR = hazard ratio; CI = confidence interval</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Table 1. Odds ratios of treatment initiation with NOACs relative to treatment initiation with VKAs by patient characteristics in patients diagnosed with NVAF in or after</head><note type="other">FIGURE LEGENDS</note></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head></head><label></label><figDesc><div><p><s>January 2011 according to treatment initiation with NOACs (n = 14,746) or VKAs (n = 17,685), along with the crude and adjusted ORs of treatment initiation with NOACs relative to VKAs.</s><s>Most patients started treatment within 90 days of NVAF diagnosis (84% for NOAC users, 91% for VKA users).</s><s>Age ≥ 80 years, prior myocardial infarction, prior venous thromboembolism, congestive heart failure, vascular disease, blood dyscrasias, chronic kidney disease, liver disease, and a CHA2DS-VASc score ≥ 2 were associated with the lowest probability of NOAC initiation.</s><s>In contrast, NVAF diagnosis after 2011 and delayed treatment initiation with oral anticoagulants following NVAF diagnosis (&gt;30 days) were associated with the highest probability of NOAC initiation.</s><s>Among the 17,685 patients diagnosed with NVAF in or after January 2011 initiating VKAs, 4763 (27%) switched from VKAs to NOACs during follow-up (Table</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Figure 1 .Figure 2 .</head><label>12</label><figDesc><div><p><s>Figure 1.</s><s>Flowchart of study cohort formation</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>January 2011 Initiating NOACs Initiating VKAs Crude OR Adjusted* OR (95% CI)</head><label></label><figDesc></figDesc><table><row><cell></cell><cell cols="3">Initiating NOACs Initiating VKAs Crude OR</cell><cell>Adjusted* OR (95% CI)</cell></row><row><cell>Prior bleeding events</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Intracranial hemorrhage</cell><cell>0.99%</cell><cell>1.45%</cell><cell>0.68</cell><cell>0.86 (0.68-1.10)</cell></row><row><cell>Gastrointestinal hemorrhage</cell><cell>2.32%</cell><cell>3.32%</cell><cell>0.69</cell><cell>0.93 (0.79-1.09)</cell></row><row><cell>Other bleeding events</cell><cell>4.64%</cell><cell>7.93%</cell><cell>0.56</cell><cell>0.83 (0.74-0.93)</cell></row><row><cell>Number of patients Blood dyscrasias</cell><cell>14,746 1.17%</cell><cell>17,685 3.36%</cell><cell>0.34</cell><cell>0.58 (0.48-0.70)</cell></row><row><cell>Age, mean (SD) Predisposition to falls</cell><cell>75.07 (9.18) 8.97%</cell><cell>76.78 (9.07) 13.10%</cell><cell>0.65</cell><cell>0.96 (0.89-1.05)</cell></row><row><cell>40-49 Dementia or schizophrenia</cell><cell>0.89% 4.96%</cell><cell>0.63% 7.75%</cell><cell>1.00 0.62</cell><cell>1.00 (Reference) 0.95 (0.85-1.06)</cell></row><row><cell>50-59 Chronic kidney disease</cell><cell>3.69% 4.30%</cell><cell>2.81% 16.06%</cell><cell>0.93 0.23</cell><cell>0.94 (0.68-1.28) 0.35 (0.32-0.39)</cell></row><row><cell>60-69 Liver disease</cell><cell>20.43% 1.27%</cell><cell>14.60% 2.40%</cell><cell>0.99 0.53</cell><cell>1.03 (0.77-1.38) 0.77 (0.63-0.94)</cell></row><row><cell>70-79 Cancer</cell><cell>40.12% 14.33%</cell><cell>34.90% 15.60%</cell><cell>0.81 0.91</cell><cell>0.87 (0.66-1.16) 0.96 (0.90-1.03)</cell></row><row><cell>≥80 Prior use of ASA</cell><cell>34.88% 33.79%</cell><cell>47.06% 28.05%</cell><cell>0.52 1.31</cell><cell>0.55 (0.41-0.73) 1.10 (1.04-1.17)</cell></row><row><cell>Male sex Prior use of clopidogrel</cell><cell>49.61% 5.02%</cell><cell>48.53% 5.97%</cell><cell>1.04 0.83</cell><cell>1.04 (0.99-1.10) 0.88 (0.79-0.98)</cell></row><row><cell>Calendar year of NVAF diagnosis CHA 2 DS 2 -VASc **</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>2011 0</cell><cell>14.43% 2.75%</cell><cell>33.79% 1.44%</cell><cell>1.00 1.00 (Reference)</cell><cell>1.00 (Reference)</cell></row><row><cell>2012 1</cell><cell>19.21% 11.32%</cell><cell>31.05% 6.08%</cell><cell>1.45 0.97 (0.82-1.16)</cell><cell>1.72 (1.60-1.85)</cell></row><row><cell>2013 ≥2</cell><cell>30.38% 85.94%</cell><cell>22.34% 92.48%</cell><cell>3.18 0.49 (0.42-0.57)</cell><cell>4.78 (4.44-5.14)</cell></row><row><cell>2014</cell><cell>35.98%</cell><cell>12.81%</cell><cell>6.58</cell><cell>9.09 (8.40-9.84)</cell></row><row><cell cols="2">Time from NVAF diagnosis to treatment initiation</cell><cell></cell><cell></cell><cell></cell></row><row><cell>0-14 days</cell><cell>70.17%</cell><cell>78.90%</cell><cell>1.00</cell><cell>1.00 (Reference)</cell></row><row><cell>15-30 days</cell><cell>5.95%</cell><cell>5.94%</cell><cell>1.13</cell><cell>1.00 (0.90-1.11)</cell></row><row><cell>31-60 days</cell><cell>4.86%</cell><cell>4.43%</cell><cell>1.23</cell><cell>1.23 (1.09-1.39)</cell></row><row><cell>61-90 days</cell><cell>2.40%</cell><cell>2.14%</cell><cell>1.26</cell><cell>1.38 (1.16-1.63)</cell></row><row><cell>91-180 days</cell><cell>4.16%</cell><cell>2.72%</cell><cell>1.72</cell><cell>2.20 (1.91-2.52)</cell></row><row><cell>181-365 days</cell><cell>4.12%</cell><cell>2.56%</cell><cell>1.81</cell><cell>2.56 (2.22-2.95)</cell></row><row><cell>&gt;365 days</cell><cell>8.33%</cell><cell>3.31%</cell><cell>2.83</cell><cell>6.24 (5.54-7.03)</cell></row><row><cell>Inpatient NVAF diagnosis</cell><cell>23.10%</cell><cell>43.13%</cell><cell>0.40</cell><cell>0.86 (0.80-0.92)</cell></row><row><cell>Cardiovascular comorbidities</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Arterial hypertension</cell><cell>45.23%</cell><cell>57.87%</cell><cell>0.60</cell><cell>0.98 (0.93-1.04)</cell></row><row><cell>Myocardial infarction</cell><cell>7.28%</cell><cell>17.25%</cell><cell>0.38</cell><cell>0.54 (0.50-0.59)</cell></row><row><cell>Diabetes mellitus</cell><cell>25.0%</cell><cell>32.48%</cell><cell>0.69</cell><cell>0.80 (0.75-0.84)</cell></row><row><cell>Venous thromboembolism</cell><cell>2.83%</cell><cell>7.41%</cell><cell>0.36</cell><cell>0.46 (0.41-0.52)</cell></row><row><cell>Congestive heart failure</cell><cell>9.86%</cell><cell>19.52%</cell><cell>0.45</cell><cell>0.76 (0.70-0.82)</cell></row><row><cell>Ischemic stroke</cell><cell>5.05%</cell><cell>7.77%</cell><cell>0.63</cell><cell>0.89 (0.80-0.99)</cell></row><row><cell>Vascular disease</cell><cell>4.73%</cell><cell>10.94%</cell><cell>0.40</cell><cell>0.69 (0.62-0.76)</cell></row></table><note><p><s>* Adjusted for all variables listed in the table except for the CHA 2 DS 2 -VASc categories.</s><s>** Risk estimates for the CHA 2 DS 2 -VASc categories were calculated in a separate model.</s><s>NOACs = non-vitamin K antagonist oral anticoagulants; VKAs = vitamin K antagonists; NVAF = non-valvular atrial fibrillation; SD = standard deviation; ASA = acetylsalicylic acid; CHA2DS2-VASc = congestive heart failure, arterial hypertension, age ≥ 75 (doubled), diabetes mellitus, stroke (doubled), vascular disease, age 65-74, sex category: female sex; OR = odds ratio; CI = confidence interval</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 2 . Hazard ratios of switching from initial VKA treatment to a NOAC by patient characteristics in patients diagnosed with NVAF in or after January 2011 Remain on VKAs Switch to NOACs Crude HR Adjusted* HR (95% CI)</head><label>2</label><figDesc><div><p><s>Adjusted for all variables listed in the table except for the CHA 2 DS 2 -VASc categories.</s><s>** Risk estimates for the CHA 2 DS 2 -VASc categories were calculated in a separate model.</s></p></div></figDesc><table><row><cell>Number of patients</cell><cell>12,922</cell><cell>4763</cell><cell></cell><cell></cell></row><row><cell>Age, mean (SD)</cell><cell>78.6 (9.3)</cell><cell>76.0 (8.6)</cell><cell></cell><cell></cell></row><row><cell>40-49</cell><cell>0.68%</cell><cell>0.48%</cell><cell>1.00</cell><cell>1.00 (Reference)</cell></row><row><cell>50-59</cell><cell>2.65%</cell><cell>3.25%</cell><cell>1.58</cell><cell>1.61 (1.04-2.49)</cell></row><row><cell>60-69</cell><cell>13.12%</cell><cell>18.60%</cell><cell>1.70</cell><cell>1.60 (1.05-2.46)</cell></row><row><cell>70-79</cell><cell>32.72%</cell><cell></cell><cell>1.59</cell><cell>1.49 (0.96-2.31)</cell></row><row><cell>≥80</cell><cell>50.83%</cell><cell>36.85%</cell><cell>1.11</cell><cell>1.05 (0.67-1.65)</cell></row><row><cell>Male sex</cell><cell>48.83%</cell><cell>47.70%</cell><cell>0.97</cell><cell>1.03 (0.88-1.21)</cell></row><row><cell>Calendar year of NVAF diagnosis</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>2011</cell><cell>31.57%</cell><cell>39.83%</cell><cell>1.00</cell><cell>1.00 (Reference)</cell></row><row><cell>2012</cell><cell>30.79%</cell><cell>31.77%</cell><cell>1.05</cell><cell>1.09 (1.02-1.17)</cell></row><row><cell>2013</cell><cell>22.98%</cell><cell>20.62%</cell><cell>1.33</cell><cell>1.46 (1.34-1.58)</cell></row><row><cell>2014</cell><cell>14.66%</cell><cell>7.79%</cell><cell>1.57</cell><cell>1.69 (1.50-1.91)</cell></row><row><cell cols="2">Time from NVAF diagnosis to VKA initiation</cell><cell></cell><cell></cell><cell></cell></row><row><cell>0-6 months</cell><cell>93.58%</cell><cell>95.65%</cell><cell>1.00</cell><cell>1.00 (Reference)</cell></row><row><cell>6 months-1 year</cell><cell>2.68%</cell><cell>2.23%</cell><cell>0.99</cell><cell>1.00 (0.83-1.22)</cell></row><row><cell>1-2 years</cell><cell>2.43%</cell><cell>1.47%</cell><cell>0.85</cell><cell>0.93 (0.73-1.18)</cell></row><row><cell>2-4 years</cell><cell>1.32%</cell><cell>0.65%</cell><cell>1.05</cell><cell>1.21 (0.85-1.73)</cell></row><row><cell>Inpatient NVAF diagnosis</cell><cell>44.73%</cell><cell>38.78%</cell><cell>0.79</cell><cell>1.02 (0.95-1.10)</cell></row><row><cell>Cardiovascular comorbidities</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Arterial hypertension</cell><cell>58.83%</cell><cell>55.26%</cell><cell>0.86</cell><cell>1.06 (0.95-1.18)</cell></row><row><cell>Myocardial infarction</cell><cell>19.11%</cell><cell>12.20%</cell><cell>0.67</cell><cell>0.73 (0.66-0.80)</cell></row><row><cell>Diabetes mellitus</cell><cell>33.40%</cell><cell>29.98%</cell><cell>0.91</cell><cell>0.99 (0.89-1.10)</cell></row><row><cell>Venous thromboembolism</cell><cell>8.47%</cell><cell>4.53%</cell><cell>0.57</cell><cell>0.58 (0.50-0.67)</cell></row><row><cell>Congestive heart failure</cell><cell>21.07%</cell><cell>15.31%</cell><cell>0.79</cell><cell>1.01 (0.89-1.14)</cell></row><row><cell>Ischemic stroke</cell><cell>7.85%</cell><cell>7.54%</cell><cell>0.96</cell><cell>1.12 (0.91-1.38)</cell></row><row><cell>Vascular disease</cell><cell>12.06%</cell><cell>7.92%</cell><cell>0.71</cell><cell>0.81 (0.67-0.97)</cell></row><row><cell>Prior bleeding events</cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table><note><p><s>*</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head>Table 3 . Hazard ratios of discontinuation of anticoagulation treatment by patient characteristics in patients diagnosed with NVAF in or after January 2011 Continuous treatment Treatment discontinuation Crude HR Adjusted HR* (95% CI)</head><label>3</label><figDesc><div><p><s>Adjusted for all variables listed in the table except for the CHA 2 DS 2 -VASc categories.</s><s>** Risk estimates for the CHA 2 DS 2 -VASc categories were calculated in a separate model.</s></p></div></figDesc><table><row><cell>Number of patients</cell><cell>14,849</cell><cell>17,582</cell><cell></cell><cell></cell></row><row><cell cols="2">Treatment initiation with NOACs vs VKAs 60.38%</cell><cell>27.85%</cell><cell>0.47</cell><cell>0.45 (0.44-0.47)</cell></row><row><cell>Age, mean (SD)</cell><cell>77.27 (9.06)</cell><cell>76.15 (9.33)</cell><cell></cell><cell></cell></row><row><cell>40-49</cell><cell>0.52%</cell><cell>1.01%</cell><cell>1.00</cell><cell>1.00 (Reference)</cell></row><row><cell>50-59</cell><cell>2.66%</cell><cell>3.87%</cell><cell>0.71</cell><cell>0.74 (0.62-0.88)</cell></row><row><cell>60-69</cell><cell>16.43%</cell><cell>18.22%</cell><cell>0.56</cell><cell>0.59 (0.50-0.69)</cell></row><row><cell></cell><cell>36.91%</cell><cell>37.70%</cell><cell>0.53</cell><cell>0.54 (0.46-0.63)</cell></row><row><cell>≥80</cell><cell>43.48%</cell><cell>39.20%</cell><cell>0.49</cell><cell>0.47 (0.40-0.55)</cell></row><row><cell>Male sex</cell><cell>47.22%</cell><cell>51.16%</cell><cell>1.15</cell><cell>1.10 (1.06-1.14)</cell></row><row><cell>Calendar year of NVAF diagnosis</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>2011</cell><cell>16.56%</cell><cell>34.97%</cell><cell>1.00</cell><cell>1.00 (Reference)</cell></row><row><cell>2012</cell><cell>20.95%</cell><cell>31.26%</cell><cell>0.92</cell><cell>0.97 (0.94-1.01)</cell></row><row><cell>2013</cell><cell>27.64%</cell><cell>24.05%</cell><cell>0.81</cell><cell>1.01 (0.96-1.06)</cell></row><row><cell>2014</cell><cell>34.86%</cell><cell>9.72%</cell><cell>0.66</cell><cell>0.93 (0.87-0.99)</cell></row><row><cell cols="2">Time from NVAF diagnosis to treatment initiation</cell><cell></cell><cell></cell><cell></cell></row><row><cell>0-14 days</cell><cell>73.35%</cell><cell>76.82%</cell><cell>1.00</cell><cell>1.00 (Reference)</cell></row><row><cell>15-30 days</cell><cell>6.08%</cell><cell>5.79%</cell><cell>0.99</cell><cell>1.04 (0.97-1.11)</cell></row><row><cell>31-60 days</cell><cell>4.86%</cell><cell>4.35%</cell><cell>0.93</cell><cell>0.98 (0.90-1.07)</cell></row><row><cell>61-90 days</cell><cell>2.21%</cell><cell>2.31%</cell><cell>1.00</cell><cell>1.08 (0.96-1.21)</cell></row><row><cell>91-180 days</cell><cell>3.41%</cell><cell>3.33%</cell><cell>0.95</cell><cell>1.09 (0.99-1.20)</cell></row><row><cell>181-365 days</cell><cell>3.28%</cell><cell>3.25%</cell><cell>1.03</cell><cell>1.16 (1.05-1.29)</cell></row><row><cell>&gt;365 days</cell><cell>6.81%</cell><cell>4.14%</cell><cell>0.93</cell><cell>1.13 (1.03-1.24)</cell></row><row><cell>Inpatient NVAF diagnosis</cell><cell>29.57%</cell><cell>39.29%</cell><cell>1.13</cell><cell>0.98 (0.94-1.02)</cell></row><row><cell>Cardiovascular comorbidities</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Arterial hypertension</cell><cell>49.98%</cell><cell>54.66%</cell><cell>1.01</cell><cell>0.96 (0.92-0.99)</cell></row><row><cell>Myocardial infarction</cell><cell>10.83%</cell><cell>14.95%</cell><cell>1.30</cell><cell>1.16 (1.11-1.22)</cell></row><row><cell>Diabetes mellitus</cell><cell>28.83%</cell><cell>29.38%</cell><cell>0.99</cell><cell>0.90 (0.87-0.93)</cell></row><row><cell>Venous thromboembolism</cell><cell>4.29%</cell><cell>6.55%</cell><cell>1.35</cell><cell>1.13 (1.05-1.21)</cell></row><row><cell>Congestive heart failure</cell><cell>14.21%</cell><cell>16.21%</cell><cell>1.13</cell><cell>1.00 (0.95-1.05)</cell></row></table><note><p><s>* NVAF = non-valvular atrial fibrillation; NOACs = non-vitamin K antagonist oral anticoagulants; VKAs = vitamin K antagonists; SD = standard deviation; ASA = acetylsalicylic acid; CHA2DS2-VASc = congestive heart failure, arterial hypertension, age ≥ 75 (doubled), diabetes mellitus, stroke (doubled), vascular disease, age 65-74, sex category: female sex; HR = hazard ratio; CI = confidence interval</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_3"><head>Table 4 . Hazard ratios of discontinuation of NOAC treatment relative to VKA treatment in patients with NVAF diagnosed in or after January 2011 for different grace periods</head><label>4</label><figDesc><div><p><s>Adjusted for age, sex, calendar year of NVAF diagnosis, time from NVAF diagnosis to treatment initiation, inpatient NVAF diagnosis, arterial hypertension, myocardial infarction, diabetes mellitus, venous thromboembolism, congestive heart failure, ischemic stroke, vascular disease, intracranial hemorrhage, gastrointestinal hemorrhage, other bleeding events, blood dyscrasias, predisposition to falls, dementia or schizophrenia, chronic kidney disease, liver disease, cancer, and prior use of acetylsalicylic acid or clopidogrel.</s></p></div></figDesc><table><row><cell></cell><cell>Crude HR</cell><cell>Adjusted* HR (95% CI)</cell></row><row><cell>Grace period of 30 days</cell><cell>0.47</cell><cell>0.45 (0.44-0.47)</cell></row><row><cell>Grace period of 60 days</cell><cell>0.65</cell><cell>0.61 (0.57-0.64)</cell></row><row><cell>Grace period of 50%</cell><cell>0.41</cell><cell>0.42 (0.41-0.44)</cell></row></table><note><p><s>*</s></p></note></figure>
		</body>
		<back>
			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>ACKNOWLEDGMENTS</head><p><s>The sponsors were not directly involved in the design and conduct of the study; the collection, management, analysis, and interpretation of the data; or the preparation, review, or approval of the manuscript.</s><s>Bayer was invited to comment on the study protocol and the manuscript.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>CONFLICT OF INTEREST</head><p><s>Professor Suissa has received research grants from Bayer Pharma, Boehringer Ingelheim, and Bristol-Myers-Squibb, and has participated in advisory board meetings or as speaker for AstraZeneca, Boehringer Ingelheim, and Novartis.</s><s>Dr. Douros, Dr. Renoux and Ms Coulombe do not have any conflicts of interest to disclose.</s></p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Status of the epidemiology of atrial fibrillation</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">B</forename><surname>Kannel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">J</forename><surname>Benjamin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">The Medical clinics of North America</title>
		<imprint>
			<biblScope unit="volume">92</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="17" to="40" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<monogr>
		<title level="m" type="main">AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">T</forename><surname>January</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">S</forename><surname>Wann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Alpert</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Heart Association Task Force on practice guidelines and the Heart Rhythm Society</title>
		<author>
			<persName><surname>Cardiology/American</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Circulation</title>
		<imprint>
			<biblScope unit="volume">130</biblScope>
			<biblScope unit="issue">23</biblScope>
			<biblScope unit="page" from="e199" to="267" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Incidence, mortality, and sex differences of nonvalvular atrial fibrillation: a population-based study</title>
		<author>
			<persName><forename type="first">C</forename><surname>Renoux</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Patenaude</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Suissa</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Journal of the American Heart Association</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page">e001402</biblScope>
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines</title>
		<author>
			<persName><forename type="first">J</forename><surname>Ansell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Hirsh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Hylek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Jacobson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Crowther</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Palareti</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Chest</title>
		<imprint>
			<biblScope unit="volume">133</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="160" to="198" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
	<note>8th Edition. Suppl</note>
</biblStruct>

<biblStruct xml:id="b5">
	<monogr>
		<title level="m" type="main">A Summary of the Literature Evaluating Adherence and Persistence with Oral Anticoagulants in Atrial Fibrillation. American journal of cardiovascular drugs : drugs, devices, and other interventions</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">O</forename><surname>Obamiro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Chalmers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">R</forename><surname>Bereznicki</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2016">2016</date>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page" from="349" to="363" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">T</forename><surname>Ruff</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">P</forename><surname>Giugliano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Braunwald</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">383</biblScope>
			<biblScope unit="issue">9921</biblScope>
			<biblScope unit="page" from="955" to="962" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Therapy persistence in newly diagnosed non-valvular atrial fibrillation treated with warfarin or NOAC. A cohort study</title>
		<author>
			<persName><forename type="first">C</forename><surname>Martinez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Katholing</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Wallenhorst</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">B</forename><surname>Freedman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Thrombosis and haemostasis</title>
		<imprint>
			<biblScope unit="volume">115</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="31" to="39" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Dynamics of vitamin K antagonist and new oral anticoagulants use in atrial fibrillation: a Danish drug utilization study</title>
		<author>
			<persName><forename type="first">A</forename><surname>Pottegard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">K</forename><surname>Poulsen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Larsen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Hallas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Journal of thrombosis and haemostasis : JTH</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="1413" to="1418" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Effect of Adherence to Oral Anticoagulants on Risk of Stroke and Major Bleeding Among Patients With Atrial Fibrillation</title>
		<author>
			<persName><forename type="first">X</forename><surname>Yao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">S</forename><surname>Abraham</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">C</forename><surname>Alexander</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Journal of the American Heart Association</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="issue">2</biblScope>
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Higher persistence in newly diagnosed nonvalvular atrial fibrillation patients treated with dabigatran versus warfarin</title>
		<author>
			<persName><forename type="first">M</forename><surname>Zalesak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Siu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Francis</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Circulation Cardiovascular quality and outcomes</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="567" to="574" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Major Bleeding Complications and Persistence With Oral Anticoagulation in Non-Valvular Atrial Fibrillation: Contemporary Findings in Real-Life Danish Patients</title>
		<author>
			<persName><forename type="first">M</forename><surname>Lamberts</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Staerk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">B</forename><surname>Olesen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Journal of the American Heart Association</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="issue">2</biblScope>
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Risk of bleeding and arterial thromboembolism in patients with non-valvular atrial fibrillation either maintained on a vitamin K antagonist or switched to a non-vitamin K-antagonist oral anticoagulant: a retrospective, matched-cohort study</title>
		<author>
			<persName><forename type="first">K</forename><surname>Bouillon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Bertrand</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Maura</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">O</forename><surname>Blotiere</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Ricordeau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Zureik</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">The Lancet Haematology</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="e150" to="159" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<monogr>
		<title level="m" type="main">Clinical events preceding switching and discontinuation of oral anticoagulant treatment in patients with atrial fibrillation. Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology</title>
		<author>
			<persName><forename type="first">M</forename><surname>Hellfritzsch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">L</forename><surname>Grove</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">E</forename><surname>Husted</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2016">2016</date>
			<biblScope unit="page">241</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Early real-world evidence of persistence on oral anticoagulants for stroke prevention in non-valvular atrial fibrillation: a cohort study in UK primary care</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Johnson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Lefevre</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">L</forename><surname>Collings</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">BMJ open</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page">e011471</biblScope>
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Rheumatoid arthritis, its treatments, and the risk of tuberculosis in Quebec</title>
		<author>
			<persName><forename type="first">P</forename><surname>Brassard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Lowe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Bernatsky</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Kezouh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Suissa</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Canada. Arthritis and rheumatism</title>
		<imprint>
			<biblScope unit="volume">61</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="300" to="304" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<monogr>
		<title level="m" type="main">Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. American journal of respiratory and critical care medicine</title>
		<author>
			<persName><forename type="first">P</forename><surname>Ernst</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">V</forename><surname>Gonzalez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Brassard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Suissa</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2007">2007</date>
			<biblScope unit="volume">176</biblScope>
			<biblScope unit="page" from="162" to="166" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Inhaled and nasal glucocorticoids and the risks of ocular hypertension or open-angle glaucoma</title>
		<author>
			<persName><forename type="first">E</forename><surname>Garbe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Lelorier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">F</forename><surname>Boivin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Suissa</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Jama</title>
		<imprint>
			<biblScope unit="volume">277</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="722" to="727" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Association of inhaled corticosteroid use with cataract extraction in elderly patients</title>
		<author>
			<persName><forename type="first">E</forename><surname>Garbe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Suissa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Lelorier</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Jama</title>
		<imprint>
			<biblScope unit="volume">280</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="539" to="543" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">The use of prescription claims databases in pharmacoepidemiological research: the accuracy and comprehensiveness of the prescription claims database in Quebec</title>
		<author>
			<persName><forename type="first">R</forename><surname>Tamblyn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Lavoie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Petrella</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Monette</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Journal of clinical epidemiology</title>
		<imprint>
			<biblScope unit="volume">48</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page" from="999" to="1009" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Questionable prescribing for elderly patients in Quebec</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">M</forename><surname>Tamblyn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Mcleod</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Abrahamowicz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">CMAJ : Canadian Medical Association journal = journal de l&apos;Association medicale canadienne</title>
		<imprint>
			<biblScope unit="volume">150</biblScope>
			<biblScope unit="issue">11</biblScope>
			<biblScope unit="page" from="1801" to="1809" />
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Validation of diagnostic codes within medical services claims</title>
		<author>
			<persName><forename type="first">M</forename><surname>Wilchesky</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">M</forename><surname>Tamblyn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Huang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Journal of clinical epidemiology</title>
		<imprint>
			<biblScope unit="volume">57</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="131" to="141" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Long-term vitamin K antagonists treatment patterns of Non-Valvular Atrial Fibrillation (NVAF): a population-based cohort study</title>
		<author>
			<persName><forename type="first">C</forename><surname>Renoux</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Coulombe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Suissa</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">BMC cardiovascular disorders</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page">84</biblScope>
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Hematologic malignant neoplasms after drug exposure in rheumatoid arthritis</title>
		<author>
			<persName><forename type="first">S</forename><surname>Bernatsky</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">E</forename><surname>Clarke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Suissa</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Archives of internal medicine</title>
		<imprint>
			<biblScope unit="volume">168</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="378" to="381" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factorbased approach: the euro heart survey on atrial fibrillation</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">Y</forename><surname>Lip</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Nieuwlaat</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Pisters</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Lane</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">J</forename><surname>Crijns</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Chest</title>
		<imprint>
			<biblScope unit="volume">137</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="263" to="272" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<monogr>
		<title level="m" type="main">Underuse of oral anticoagulants in atrial fibrillation: a systematic review. The American journal of medicine</title>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">M</forename><surname>Ogilvie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Newton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Welner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Cowell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">Y</forename><surname>Lip</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2010">2010</date>
			<biblScope unit="volume">123</biblScope>
			<biblScope unit="page" from="638" to="645" />
		</imprint>
	</monogr>
	<note>e634</note>
</biblStruct>

<biblStruct xml:id="b26">
	<monogr>
		<title level="m" type="main">National Trends in Ambulatory Oral Anticoagulant Use. The American journal of medicine</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">D</forename><surname>Barnes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Lucas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">C</forename><surname>Alexander</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><forename type="middle">D</forename><surname>Goldberger</surname></persName>
		</author>
		<imprint>
			<date type="published" when="1302">2015. e1302</date>
			<biblScope unit="volume">128</biblScope>
			<biblScope unit="page" from="1300" to="1305" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Trends in the prescription of novel oral anticoagulants in UK primary care</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">Y</forename><surname>Loo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Dell'aniello</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Huiart</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Renoux</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">British journal of clinical pharmacology</title>
		<imprint>
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Dabigatran versus warfarin in patients with atrial fibrillation</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Connolly</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Ezekowitz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Yusuf</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">The New England journal of medicine</title>
		<imprint>
			<biblScope unit="volume">361</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="1139" to="1151" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Apixaban versus warfarin in patients with atrial fibrillation</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">B</forename><surname>Granger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Alexander</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Mcmurray</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">The New England journal of medicine</title>
		<imprint>
			<biblScope unit="volume">365</biblScope>
			<biblScope unit="issue">11</biblScope>
			<biblScope unit="page" from="981" to="992" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Rivaroxaban versus warfarin in nonvalvular atrial fibrillation</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">R</forename><surname>Patel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">W</forename><surname>Mahaffey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Garg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">The New England journal of medicine</title>
		<imprint>
			<biblScope unit="volume">365</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="883" to="891" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Camm</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">Y</forename><surname>Lip</surname></persName>
		</author>
		<author>
			<persName><forename type="first">De</forename><surname>Caterina</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">European heart journal</title>
		<imprint>
			<biblScope unit="volume">33</biblScope>
			<biblScope unit="issue">21</biblScope>
			<biblScope unit="page" from="2719" to="2747" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Comparison of treatment persistence with different oral anticoagulants in patients with atrial fibrillation</title>
		<author>
			<persName><forename type="first">T</forename><surname>Forslund</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Wettermark</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Hjemdahl</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">European journal of clinical pharmacology</title>
		<imprint>
			<biblScope unit="volume">72</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="329" to="338" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">Persistence with denosumab and zoledronic acid among older women: a population-based cohort study</title>
		<author>
			<persName><forename type="first">E</forename><surname>Tremblay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Perreault</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Dorais</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Archives of osteoporosis</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page">30</biblScope>
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
